PUBLIC COMPANY
save$AKTSAktis Oncology, Inc.
$AKTS17.04-2.35%Boston, MA, USupdated 5d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipelineCity Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.biospace · 1mo ago
- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.biospace · 3mo ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that